학술논문
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, March 2024, 25(3):376-387)
Subject
Language
English
ISSN
14745488
14702045
14702045